NasdaqGS:SYREBiotechs
Spyre Therapeutics (SYRE) Stock Valuation After SKYWAY Phase 2 Enrollment And Upcoming SPY072 Data
Spyre Therapeutics (SYRE) stock is reacting to fresh clinical updates after the company completed enrollment in all sub studies of its SKYWAY Phase 2 trial of SPY072 in multiple rheumatic disease indications.
See our latest analysis for Spyre Therapeutics.
At a share price of $80.79, Spyre Therapeutics has seen strong momentum recently, with a 7 day share price return of 9.7%, a 90 day share price return of 83.3% and a year to date share price return of 164.2%. The 1 year total shareholder...